TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis.

21 окт. 2019 г. · Trikafta is the first approved treatment that is effective for cystic fibrosis patients 12 years and older with at least one F508del mutation.

13 сент. 2023 г. · FDA Approved: Yes (First approved October 21, 2019) ; Brand name: Trikafta ; Generic name: elexacaftor/tezacaftor/ivacaftor and ivacaftor ; Dosage ...

26 апр. 2023 г. · FDA Approves Trikafta for Children Ages 2 Through 5 Years With Certain CF Mutations. With this approval, approximately 2,250 children in the ...

26 апр. 2023 г. · TRIKAFTA® was previously approved by the FDA for use in people with CF 6 years and older with at least one F508del mutation or a mutation in ...

TRIKAFTA is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one copy of the F508del ...

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic ...

TRIKAFTA is for the treatment of CF in people age 2 years and older who have at least one copy of the F508del mutation or one of the following CF gene mutations ...

The U.S. Food and Drug Administration has approved the use of Trikafta® (elexacaftor/tezacaftor/ivacaftor) for children with cystic fibrosis ages 6 through 11 ...

27 апр. 2023 г. · The FDA expanded the indication for elexacaftor, tezacaftor, and ivacaftor (Trikafta) in cystic fibrosis to include even younger children, ...